[Ip-health] Bayer compulsory licence appeal rejected - MSF welcomes decision

Shailly shailly.17 at gmail.com
Mon Sep 17 05:19:07 PDT 2012


IPAB Chennai order on Bayer/Natco matter regarding Compulsory License is
out and can be read from here:

http://donttradeourlivesaway.wordpress.com/2012/09/17/ipab-chennai-order-dismissed-the-cl-stay-petition-of-bayer/



Regards

Shailly Gupta
MSF Access Campaign
New Delhi, India

On Mon, Sep 17, 2012 at 12:48 PM, leena menghaney
<leenamenghaney at gmail.com>wrote:

> Dear All,
>
> Just to highlight once again that the IPAB order on Bayer's appeal has
> not been made public as yet. A final analysis can only be undertaken
> once the order is published.
>
> The order is not expected before Wednesday.
>
> The Hindu has confirmed the rejection of the appeal filed by Bayer
> before the IPAB through its press reports.
>
>
> Leena Menghaney
>
>
>
> On Mon, Sep 17, 2012 at 3:38 PM, Joanna Keenan-Siciliano
> <joanna.l.keenan at gmail.com> wrote:
> > The Intellectual Property Appellate Board of Chennai has dismissed the
> plea
> > by German pharmaceutical company Bayer, which was seeking a stay on the
> > compulsory licence issued by the Indian Patent Controller to Indian
> company
> > Natco to manufacture generic versions of the anti cancer drug sorafenib
> > tosylate.
> >
> > *"This decision once again affirms that governments can and should act in
> > the interest of public health to bring the price of patented medicines
> > down,"* said Leena Menghaney, of Médecins Sans Frontières' Access
> Campaign.
> > "*The high prices caused by patents in India are a growing problem that
> > needs to be grappled with: one year's treatment costs over $1700 for one
> of
> > the newer HIV medicines we use in our project in Mumbai, and will be
> > needing across the developing world. This price needs to come down, and
> we
> > hope that the routine use of compulsory licensing may be one way of
> making
> > this happen." *
> >
> >
> >
> > While MSF has not yet seen the judgment from India's Intellectual
> Property
> > Appellate Board, we welcome the decision to uphold the grant of a
> > compulsory licence issued in March this year to allow a more affordable
> > version of liver and kidney cancer drug, sorafenib tosylate, to be
> > produced. The move brought the price of the patented drug down from over
> > US$5,500 per month to $175 per month; a price reduction of 97 per cent.
> > Bayer is being paid a six per cent royalty on sales by Natco, the generic
> > manufacturer who received the licence.
> >
> >
> >
> > India’s first compulsory licence was seen as a prospective watershed for
> > affordable access to patented medicines, by potentially opening the way
> for
> > other life-saving drugs - such as the newest drugs used to treat HIV –
> now
> > patented in India and priced out of reach to be produced by generic
> > companies for use across the developing world at a fraction of the price.
> >
> >
> > *Joanna Keenan*
> > Press Officer
> > Médecins Sans Frontières - Access Campaign
> > E: joanna.keenan[at]geneva.msf.org
> > T: twitter.com/joanna_keenan
> >
> > msfaccess.org
> > twitter.com/MSF_access
> > facebook.com/MSFaccess
> > _______________________________________________
> > Ip-health mailing list
> > Ip-health at lists.keionline.org
> >
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>
>
>
> --
> Leena Menghaney
> Tel: 46573730/1, 9811365412
>
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>



More information about the Ip-health mailing list